List of Excipients in Branded Drug FAMCICLOVIR

Generic Drugs Containing FAMCICLOVIR

Company	Ingredient	NDC	Excipient
Teva Pharmaceuticals USA Inc	famciclovir	0093-8117	CELLULOSE, MICROCRYSTALLINE
Teva Pharmaceuticals USA Inc	famciclovir	0093-8117	CROSCARMELLOSE SODIUM
Teva Pharmaceuticals USA Inc	famciclovir	0093-8117	HYDROXYPROPYL CELLULOSE, LOW SUBSTITUTED
Teva Pharmaceuticals USA Inc	famciclovir	0093-8117	HYPROMELLOSE 2910
Teva Pharmaceuticals USA Inc	famciclovir	0093-8117	POLYDEXTROSE

What are the Most Frequently-Used Excipients in FAMCICLOVIR?

# Of NDCs	Excipient
2	ANHYDROUS LACTOSE
4	CELLULOSE, MICROCRYSTALLINE
7	CROSCARMELLOSE SODIUM
3	CROSPOVIDONE
12	HYDROXYPROPYL CELLULOSE

Famciclovir Excipient Strategy and Commercial Opportunities

Last updated: August 10, 2026

Famciclovir is an established oral antiviral with broad generic availability, limited remaining exclusivity value, and a formulation profile suited to differentiated solid-dose products. The strongest commercial opportunities are not new-molecule exclusivity plays. They are lower-cost manufacturing, improved swallowing, pediatric acceptability, rapid-dissolution products, decentralized packaging, and selected combination or adherence-oriented products.

Famciclovir is the oral prodrug of penciclovir. It is approved for herpes zoster, recurrent genital herpes, and recurrent herpes labialis in adults. The U.S. reference product, Famvir, is marketed as immediate-release tablets in 125 mg, 250 mg, and 500 mg strengths. Generic famciclovir products are available in the United States and other major markets.[1,2]

What is famciclovir and how is it formulated?

Famciclovir is a synthetic guanine nucleoside analogue prodrug. After oral administration, it is rapidly converted to penciclovir, which is phosphorylated preferentially in herpesvirus-infected cells. The active triphosphate inhibits viral DNA polymerase.[1]

The commercial formulation is an immediate-release, film-coated tablet. Its development priorities are therefore different from those for poorly absorbed or highly unstable molecules. The excipient system must support:

• Rapid disintegration and dissolution
• Consistent dose uniformity across 125 mg, 250 mg, and 500 mg strengths
• Mechanical strength during coating, packaging, and distribution
• Acceptable tablet size
• Stability against moisture and physical degradation
• Manufacturing scalability at generic-market cost targets

The FDA label identifies inactive ingredients in Famvir tablets, including lactose monohydrate, hydroxypropyl cellulose, sodium starch glycolate, magnesium stearate, titanium dioxide, polyethylene glycol, and hypromellose, although composition can vary by strength and market presentation.[1]

What are the key physicochemical formulation issues?

Famciclovir has a relatively high oral bioavailability compared with many antiviral agents, reported at approximately 77% in the prescribing information.[1] The formulation challenge is therefore usually not extreme bioavailability enhancement. The higher-value technical issues are dissolution control, tablet robustness, dose proportionality, and patient acceptability.

The product is administered in different regimens depending on indication. A single-dose regimen is used for recurrent herpes labialis in adults, while herpes zoster treatment uses 500 mg three times daily for seven days.[1] This creates a commercial rationale for products that improve one-time dosing, reduce tablet burden, or simplify administration for patients with dysphagia.

What excipients are used in famciclovir tablets?

The reference formulation uses conventional pharmaceutical excipients rather than a proprietary delivery platform. Generic manufacturers can therefore pursue standard substitution strategies, subject to regulatory comparability and product-specific requirements.

Excipient function	Representative excipients	Formulation purpose
Diluent	Lactose monohydrate, microcrystalline cellulose	Provides tablet mass and improves blend handling
Binder	Hydroxypropyl cellulose, povidone	Supports granule and tablet strength
Disintegrant	Sodium starch glycolate, croscarmellose sodium, crospovidone	Promotes rapid tablet breakup
Lubricant	Magnesium stearate, sodium stearyl fumarate	Reduces ejection force and tooling friction
Film former	Hypromellose	Produces a protective and identifiable coating
Plasticizer	Polyethylene glycol	Improves coating flexibility
Opacifier or colorant	Titanium dioxide and permitted colorants	Supports appearance and product identification

The best excipient choice depends on the manufacturing process. A wet-granulation approach can improve content uniformity and flow for lower-strength tablets. Direct compression can lower processing cost but requires stronger control of particle-size distribution, flow, segregation, and lubricant sensitivity.

Which excipient substitutions create the most value?

The highest-probability substitutions are conventional disintegrant and diluent changes. They can lower cost or improve dissolution without creating a new regulatory category.

Crospovidone may provide faster wicking and disintegration than sodium starch glycolate in some tablet matrices. Croscarmellose sodium can provide strong swelling and rapid breakup at relatively low concentrations. Microcrystalline cellulose can replace part of a lactose-based diluent system where lactose intolerance, moisture sensitivity, or supplier concentration is a concern.

Sodium stearyl fumarate may be useful where magnesium stearate over-lubrication slows dissolution. Its use can improve tablet ejection and reduce hydrophobic coating of active particles, although the benefit must be demonstrated in the final formulation.

Low-moisture excipient grades may improve stability where the active or granulation process is sensitive to water. The commercial value is greatest in hot, humid markets and in products distributed through less controlled supply chains.

What excipient strategy is best for generic famciclovir?

A practical generic strategy is a robust immediate-release formulation with a low-cost, globally sourced excipient system. The target should be equivalent dissolution across relevant pH conditions, strong tablet performance, and low manufacturing complexity.

Strategy 1: Cost-optimized conventional tablet

A conventional formulation can use lactose monohydrate or microcrystalline cellulose as the principal diluent, a standard superdisintegrant, hydroxypropyl cellulose or povidone as binder, and magnesium stearate or sodium stearyl fumarate as lubricant.

This approach has the lowest development risk. It is appropriate for tender markets, pharmacy substitution, and high-volume generic supply. The main commercial constraint is price competition. Excipient differentiation alone is unlikely to support a substantial premium.

Strategy 2: Rapid-dissolving tablet

A rapid-dissolving formulation can use a high-efficiency disintegrant, optimized granule porosity, and low lubricant concentration. The objective is faster tablet dispersion rather than a new pharmacokinetic profile.

Potential claims may include rapid disintegration or improved handling, but clinical superiority cannot be assumed. Regulatory submissions would generally need comparative dissolution and stability data. If the product is intended to be bioequivalent to an immediate-release reference, the development program must remain aligned with applicable FDA or regional bioequivalence requirements.

Strategy 3: Low-size, high-load tablet

Famciclovir dosing can create a meaningful tablet burden, especially for the 500 mg strength and multi-day herpes zoster therapy. A high-load tablet could reduce tablet dimensions by improving compaction, selecting dense excipient grades, and optimizing particle engineering.

A smaller tablet may improve swallowing, but high compaction can delay disintegration. The formulation must balance tensile strength against porosity and dissolution. This strategy has stronger commercial relevance than a minor color or coating change because it addresses a visible patient-use problem.

Strategy 4: Taste-masked dispersible or orally disintegrating product

A dispersible or orally disintegrating famciclovir product could target patients with dysphagia, older adults, and pediatric use. The main obstacle is taste. Famciclovir is not automatically suitable for direct oral disintegration without taste masking.

Potential technologies include polymeric taste-masking coatings, ion-exchange resins, lipid barriers, cyclodextrin complexes, and multiparticulate systems. Each creates new control requirements for dose uniformity, moisture protection, mouthfeel, and release in the gastrointestinal tract.

A dispersible tablet may be easier to develop than a true orally disintegrating tablet because it can be administered in water. An orally disintegrating tablet has a stronger patient-use proposition but a more demanding sensory and mechanical profile.

What formulation patents could protect famciclovir products?

New excipient combinations can create patentable subject matter, but patentability does not guarantee commercial strength. The most defensible formulation claims would usually require a specific technical relationship, such as:

• A defined famciclovir-to-disintegrant ratio producing a specified dissolution profile
• A taste-masked multiparticulate with a defined polymer barrier
• A low-size tablet with controlled tensile strength and rapid disintegration
• A moisture-resistant composition with demonstrated stability under accelerated conditions
• A dispersible tablet that maintains dose uniformity after suspension
• A specific coating system that reduces bitterness without delaying release

Broad claims covering routine use of lactose, microcrystalline cellulose, hypromellose, or magnesium stearate would face substantial prior-art risk. The relevant prior art includes Famvir disclosures, generic product formulations, antiviral tablet patents, and standard pharmaceutical formulation literature.

A stronger patent package would combine composition claims with process and performance claims. For example, a company could claim a defined granulation endpoint, particle-size distribution, tablet porosity range, and dissolution result. Such claims are narrower but may better reflect an actual manufacturing advantage.

When does famciclovir lose exclusivity?

Famciclovir lost U.S. market exclusivity many years ago. Famvir received FDA approval in 1994, and generic famciclovir products have been marketed for years.[1,3]

Milestone	Status
U.S. Famvir approval	1994
Active ingredient exclusivity	Expired
Original reference-product patent estate	Historical and commercially exhausted for ordinary generic entry
Generic U.S. availability	Yes
Current commercial focus	Price, supply reliability, formulation convenience, and market access

The Orange Book remains the relevant source for current listed patents, regulatory exclusivity, and reference-product information. Patent status should be checked against the current FDA publication and applicable national registers before filing or launch decisions.[3]

Does famciclovir have biosimilar risk?

No. Famciclovir is a small-molecule drug, not a biologic. Biosimilar pathways do not apply. Competitive risk comes from generic tablets, authorized generics where applicable, branded generics, and alternative antivirals such as acyclovir and valacyclovir.

What is the Orange Book status of famciclovir?

Famciclovir is regulated as a small-molecule prescription drug. The relevant U.S. regulatory pathway for a generic tablet is generally an abbreviated new drug application, subject to the requirements applicable to the reference-listed drug.

The principal regulatory issues are:

1. Pharmaceutical equivalence
2. Bioequivalence
3. Assay and content uniformity
4. Dissolution across relevant media
5. Stability
6. Manufacturing controls
7. Labeling conformity

A new dosage form, altered route, or materially different release profile can require a different regulatory strategy. An orally disintegrating or dispersible product may still be eligible for an abbreviated pathway if it meets the applicable criteria, but the formulation cannot be assumed to qualify solely because the active ingredient is already approved.

Which companies are challenging famciclovir exclusivity?

The competitive field is primarily generic rather than patent-litigation driven. Generic manufacturers have entered the market following expiration of the originator’s core exclusivity. Common participants in antiviral generics have included large multinational and regional suppliers, although active suppliers vary by country and time.

No current commercial assessment should rely on a historical Paragraph IV filing alone. Paragraph IV activity is relevant only when a listed patent remains operative and the filing date, certification, litigation, and settlement terms are confirmed in FDA and court records.

For famciclovir, the practical market-entry risk is more likely to involve:

• ANDA review timing
• Manufacturing inspection status
• API supply
• Pricing erosion
• Product discontinuation
• National reimbursement and tender rules
• Distribution access

What patent litigation and settlement agreements affect famciclovir?

The principal Famvir patent disputes are historical. Because the product has been generic for an extended period, any legacy litigation or settlement agreement is unlikely to determine ordinary current entry unless a specific market retains an enforceable secondary patent.

A launch review should distinguish among:

• Expired compound patents
• Expired formulation patents
• Method-of-use patents
• Current Orange Book-listed patents
• Non-Orange Book patents
• Regulatory exclusivity
• Patent settlements that affected historical launch dates

Method-of-use patents are less commercially powerful where generic labeling can omit protected indications, but the risk depends on the scope of the claims, prescriber behavior, state or national law, and the product’s proposed labeling.

What commercial opportunities exist for famciclovir excipient innovation?

The most credible opportunities fall into five segments.

Dysphagia and adherence products

Smaller tablets, dispersible tablets, and orally disintegrating systems can target older adults and patients who have difficulty swallowing conventional tablets. The value proposition is patient convenience rather than improved antiviral efficacy.

Pediatric formulations

Famciclovir is not broadly positioned as a pediatric product in the U.S. reference labeling. A pediatric formulation would require a separate regulatory and clinical strategy. A liquid, powder for reconstitution, or dispersible tablet could address dosing flexibility, but palatability and age-appropriate dosing would be central development risks.[1]

Emerging-market products

Hot-climate stability, low-cost excipients, simple packaging, and reduced tablet size can improve competitiveness in markets where supply reliability and distribution conditions are more important than premium branding.

Hospital and institutional packaging

Unit-dose blister packs, calendar packaging, and indication-specific kits could support adherence during short treatment courses. The commercial opportunity is strongest where pharmacies and institutions value reduced dispensing errors.

Combination or co-packaged antiviral products

A famciclovir combination product would face clinical, regulatory, and patent scrutiny. A co-packaged regimen may be more practical than a fixed-dose combination where dosing schedules differ by indication. Co-packaging can improve adherence but may not create strong intellectual property protection.

How does famciclovir compare with acyclovir and valacyclovir?

Attribute	Famciclovir	Acyclovir	Valacyclovir
Drug type	Oral prodrug of penciclovir	Active antiviral	Oral prodrug of acyclovir
Main dosage forms	Immediate-release tablets	Tablets, capsules, suspension, topical products	Immediate-release tablets
U.S. reference approval	Famvir, 1994	Zovirax, 1980s	Valtrex, 1990s
Generic competition	Extensive	Extensive	Extensive
Main formulation opportunity	Swallowing, dispersible dosing, tablet size	Liquids, topical systems, renal-use convenience	Dose convenience and tablet optimization
Primary commercial pressure	Low price and substitution	Very low cost and broad availability	Strong brand recognition and dosing convenience

Valacyclovir generally has a stronger convenience proposition because dosing can be less frequent for some indications. Famciclovir can compete through tolerability, regimen fit, supply reliability, and differentiated administration formats.

How strong is the patent estate for famciclovir?

The legacy compound estate is commercially weak because the product has been generic for years. A new entrant would need to create value through secondary intellectual property.

IP category	Current strategic value
Original compound patent	Low after expiry
Original Famvir formulation	Low after generic entry
Broad excipient claims	Weak unless supported by unexpected results
Taste-masking claims	Moderate if technically specific
ODT or dispersible formulation	Moderate to strong if clinically useful and difficult to design around
Manufacturing-process claims	Moderate where process improves yield, stability, or impurity control
Packaging and adherence claims	Usually limited unless tied to a technical product feature
Method-of-use claims	Indication-dependent and vulnerable to label carve-outs

The strongest commercial position would combine a differentiated dosage form, a credible patient or payer benefit, and patent claims that cover both the formulation and its manufacturing process.

What manufacturing and IP barriers affect famciclovir?

Manufacturing barriers are manageable but still relevant. Famciclovir products require control of blend uniformity, tablet compression, coating, dissolution, and stability. A formulation that relies on a narrow processing window may be difficult to transfer between sites.

Key development controls include:

• API particle-size distribution
• Bulk density and flow
• Blend segregation
• Granulation endpoint
• Lubrication time
• Tablet tensile strength
• Disintegration time
• Dissolution by strength
• Coating weight gain
• Moisture exposure
• Impurity profile

The most useful process patent would cover a reproducible manufacturing advantage, such as reduced degradation, improved yield, or a stable high-drug-load tablet. A formulation patent without manufacturing reproducibility may have limited value in licensing or litigation.

What is the revenue exposure for famciclovir?

Famciclovir revenue is structurally exposed to generic price erosion. The branded Famvir opportunity is limited in markets with extensive substitution. Revenue growth is more likely to come from volume, geographic expansion, reliable supply, specialty packaging, or differentiated dosage forms.

A commercial model should evaluate:

• Annual prescription volume by indication
• Generic price per tablet
• Share of 125 mg, 250 mg, and 500 mg strengths
• Herpes zoster versus herpes simplex demand
• Tender and reimbursement pricing
• Manufacturing cost per tablet
• API cost and supplier concentration
• Incremental cost of taste masking or specialized excipients
• Regulatory cost for a new dosage form
• Expected premium over standard generic tablets

A conventional generic may offer the fastest route to revenue but the lowest margin. A dispersible or taste-masked product may support higher pricing but requires more development, clinical usability testing, and regulatory work.

Key Takeaways

• Famciclovir is a mature small-molecule antiviral with extensive generic competition.
• The strongest excipient opportunities are rapid disintegration, smaller tablets, dispersible formats, taste masking, and moisture-robust products.
• Standard excipient substitutions can improve cost and manufacturing performance but rarely support strong premium pricing.
• Pediatric and orally disintegrating products offer the clearest differentiation, subject to regulatory and palatability requirements.
• Biosimilar risk does not apply because famciclovir is not a biologic.
• Current market entry risk is driven more by generic competition, supply, pricing, and regulatory execution than by core-patent barriers.
• A defensible secondary patent estate should combine composition, performance, and manufacturing claims.
• Commercial success depends on solving a clear patient or supply-chain problem rather than merely changing excipients.

FAQs

Can famciclovir be reformulated as an oral suspension?

Yes, but an oral suspension would require demonstrated chemical and physical stability, dose uniformity, sedimentation control, preservative strategy where applicable, and acceptable palatability. A powder for reconstitution may be more practical than a ready-to-use liquid because it can reduce storage and stability burdens.

Is a famciclovir gummy or chewable tablet commercially realistic?

It is technically possible, but taste masking would be a primary development issue. The formulation must also control dose uniformity, texture, moisture uptake, and accidental pediatric exposure. A chewable product would require a clear patient-use advantage over a conventional tablet.

Could cyclodextrins improve famciclovir delivery?

Cyclodextrins could modify solubility or taste, but their value must be demonstrated in the final dosage form. Because famciclovir already has substantial oral bioavailability, a cyclodextrin system may be more commercially useful for taste masking or dispersibility than for major exposure enhancement.

Are famciclovir excipient patents likely to block generic manufacturers?

Broad excipient patents are unlikely to block ordinary generic tablets because conventional formulations are well established. A narrowly drafted patent covering a specific taste-masking system, release profile, or manufacturing process could affect a differentiated product.

What is the most attractive famciclovir product concept?

A low-size, rapidly disintegrating, taste-masked tablet or dispersible dosage form has the strongest combination of patient utility and potential secondary intellectual property. A conventional low-cost tablet remains the lower-risk option for volume-driven generic competition.

References

1. Novartis Pharmaceuticals Corporation. (2023). Famvir (famciclovir) tablets: U.S. prescribing information. U.S. Food and Drug Administration.

2. U.S. Food and Drug Administration. (2024). Drugs@FDA: FDA-approved drugs, Famvir and famciclovir products. https://www.accessdata.fda.gov/scripts/cder/daf/

3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book